Medeze Group

Medeze Group PEG

The PEG Ratio (Price/Earnings-to-Growth) of Medeze Group (MEDEZE.BK) as of Oct 27, 2026 is 4.27. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was 2.48 — a change of 72.49% (higher).

PEG

4.27

YoY

72.49%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Medeze Group is 2025 4.27 . PEG Ratio (Price/Earnings-to-Growth) of Medeze Group was 2024 2.48 . It decreases by 72.49% higher compared to the previous year.

The Medeze Group PEG history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PEG
Date
PEG
Jan 1, 2017
3.95 THB
Jan 1, 2018
5.12 THB
Jan 1, 2020
3.59 THB
Jan 1, 2021
7.15 THB
Jan 1, 2022
5.57 THB
Jan 1, 2023
3.50 THB
Jan 1, 2024
2.48 THB
Jan 1, 2025
4.27 THB
The Medeze Group PEG history
YEARPEGYoY
4.27+72.49%
2.48-29.28%
3.50-37.09%
5.57-22.13%
7.15+99.21%
3.59-29.86%
5.12+29.60%
3.95—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medeze Group Stock analysis

What does Medeze Group do? Medeze Group PLC operates as a mesenchymal stem cell bank in Thailand, offering stem cell storage services from umbilical cord tissue and adipose tissue, alongside umbilical cord blood storage. The company provides stem cell analysis, separation, cultivation, and storage services, including immune cell potential testing for Natural killer cells. Its white blood cell potential testing service segment evaluates NK cell performance and count, while the other services segment delivers research, data collection on human cellular activities, and medical laboratory tests. The sales of products segment generates revenue through dietary supplements, cosmetics, and dermo cosmetics. The company's primary customers are individuals seeking stem cell storage for future medical use, as well as those requiring immune cell testing and research services. The stem cell sample collection service segment targets expectant parents and medical institutions for cord blood and tissue storage. The white blood cell potential testing service segment serves healthcare providers and patients interested in NK cell analysis. The sales of products segment appeals to consumers purchasing dietary supplements and cosmetic products. Medeze Group PLC's revenue streams are derived from multiple segments: stem cell storage services, immune cell testing, research and laboratory services, and product sales. The stem cell sample collection and storage services form the core offering, while the white blood cell potential testing and other services provide additional value. Product sales contribute to revenue through the distribution of dietary supplements, cosmetics, and dermo cosmetics, targeting both individual consumers and healthcare-focused markets. Medeze Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medeze Group stock

PEG Ratio (Price/Earnings-to-Growth) of Medeze Group is 4.27 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Medeze Group changed from 2.48 to 4.27, representing a 72.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Medeze Group since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Medeze Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Medeze Group

All Key Metrics — Medeze Group